Lyell Immunopharma, Inc.
LYEL
$17.92
-$1.10-5.78%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.00K | 15.00K | 8.00K | 7.00K | 11.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.00K | 15.00K | 8.00K | 7.00K | 11.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 6.00K | 15.00K | 8.00K | 7.00K | 11.00K |
| SG&A Expenses | 10.62M | 10.69M | 9.79M | 14.05M | 14.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.33M | -1.59M | -1.34M | -1.41M | -1.44M |
| Total Operating Expenses | 61.48M | 37.27M | 43.31M | 56.08M | 61.75M |
| Operating Income | -61.48M | -37.25M | -43.30M | -56.08M | -61.74M |
| Income Before Tax | -140.72M | -38.85M | -42.68M | -52.20M | -191.94M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -140.72M | -38.85M | -42.68M | -52.20M | -191.94M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -140.72M | -38.85M | -42.68M | -52.20M | -191.94M |
| EBIT | -61.48M | -37.25M | -43.30M | -56.08M | -61.74M |
| EBITDA | -59.08M | -34.69M | -40.16M | -52.64M | -56.72M |
| EPS Basic | -6.86 | -2.13 | -2.89 | -3.54 | -13.71 |
| Normalized Basic EPS | -2.32 | -1.33 | -1.64 | -2.16 | -2.52 |
| EPS Diluted | -6.86 | -2.13 | -2.89 | -3.54 | -13.71 |
| Normalized Diluted EPS | -2.32 | -1.33 | -1.64 | -2.16 | -2.52 |
| Average Basic Shares Outstanding | 20.52M | 18.27M | 14.79M | 14.75M | 14.00M |
| Average Diluted Shares Outstanding | 20.52M | 18.27M | 14.79M | 14.75M | 14.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |